Prometheus Biosciences Revenue and Competitors

Location

$451.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Prometheus Biosciences's estimated annual revenue is currently $2.6M per year.(i)
  • Prometheus Biosciences's estimated revenue per employee is $25,600
  • Prometheus Biosciences's total funding is $451.8M.
  • Prometheus Biosciences's current valuation is $1.4B. (January 2022)

Employee Data

  • Prometheus Biosciences has 100 Employees.(i)
  • Prometheus Biosciences grew their employee count by 0% last year.

Prometheus Biosciences's People

NameTitleEmail/Phone
1
VP - Precision BioinformaticsReveal Email/Phone
2
General CounselReveal Email/Phone
3
VP, Biostatistics & Data ManagementReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Associate Director, Biobanking OperationsReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Director Data ManagementReveal Email/Phone
8
Chief Operating OfficerReveal Email/Phone
9
Director, Data Science and EngineeringReveal Email/Phone
10
Senior Director, Immunology Discovery & Translational SciencesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M50%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M4-50%N/AN/A
#6
$0.7M80%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1731%N/AN/A
Add Company

What Is Prometheus Biosciences?

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

keywords:N/A

$451.8M

Total Funding

100

Number of Employees

$2.6M

Revenue (est)

0%

Employee Growth %

$1.4B

Valuation

N/A

Accelerator

Prometheus Biosciences News

2022-04-20 - Prometheus Biosciences Breaks Below 200-Day Moving Average - Notable for RXDX

In trading on Monday, shares of Prometheus Biosciences Inc (Symbol: RXDX) crossed below their 200 day moving average of $31.68,...

2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a ...

... Cornerstones Health, and Imedex; and as a consultant or adviser to Boehringer Ingelheim, Gilead Sciences, Prometheus Biosciences, Takeda, UCB Biopharma,...

2022-03-30 - Prometheus Biosciences Initiates Third Phase 2 Study of ...

Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).

2020-12-15 - Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.5M10011%N/A
#2
$22M1009%N/A
#3
$16.5M1000%N/A
#4
$38.4M10011%N/A
#5
$8.8M100N/AN/A